Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension

NCT ID: NCT00575692

Last Updated: 2014-05-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study is to identify changes in the cardiovascular system in patients with pulmonary hypertension (PH) by magnetic resonance imaging (MRI). MRI is accepted as golden standard method for the evaluation of left and right ventricular morphology and function.

All patients who showed elevated pulmonary pressure in the right heart catheter investigation are assigned to MRI. Parameters derived from MRI are included in the clinical and therapeutic decisions. Well established as well as new MRI parameters are evaluated and compared to the results of right heart catheter. Further age-matched controls without known cardiac or pulmonary disease are investigated by native MRI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with suspected, latent and manifest PH and controls are investigated by MRI according to the following protocol in breathhold or free breathing (depending on the patients' breath-hold abilities). In case of elevated Creatinin values, no contrast agent is applied.

* Planning of cardiac views: Planning of 2-chamber view, short axes view and 4-chamber view.
* Morphological overview: Transversal and coronal Haste images
* Left and right heart functional and valve evaluation: Cine 2-chamber imaging, Multi-slice cine 4-chamber imaging, Cine Left and Right ventricular outflow tract imaging and Multi-slice cine short axes imaging covering the left and right ventricle for evaluation of EDV, ESV, SV, EF, CO and muscle mass.
* Phase Contrast Imaging: Flow measurements in the aorta, the pulmonary artery and the heart.
* Perfusion measurement.
* Late enhancement measurement: Multi-slice short axes view, multi-slice 2-chamber view and multi-slice 4-chamber view.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension Ventricular Function MR Phase Contrast Velocity Imaging Late Enhancement Patterns

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PulmoHypertension

Patients with suspected, latent or manifest pulmonary hypertension

No interventions assigned to this group

Controls

Controls without history of cardiac or pulmonary diseases

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Controls without history of cardiac or pulmonary diseases
* Patients with suspected PH
* Patients with latent PH
* Patients with manifest PH
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Graz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Olschewski, Horst, Prof. MD

Univ.-Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabor Kovacs, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Unitersity Graz, University Clinic of Internal Medicine, Department of Pulmonology

Ursula Reiter, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical Unitersity Graz, University Clinic of Radiology, Department of General Radiological Diagnostics

Gert Reiter, PhD

Role: PRINCIPAL_INVESTIGATOR

Siemens Medical Austria

HOrst Olschewski, M.D.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Graz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Unitersity Graz, University Clinic of Internal Medicine, Department of Pulmonology

Graz, Stmk., Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

References

Explore related publications, articles, or registry entries linked to this study.

Reiter G, Reiter U, Kovacs G, Kainz B, Schmidt K, Maier R, Olschewski H, Rienmueller R. Magnetic resonance-derived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure. Circ Cardiovasc Imaging. 2008 Jul;1(1):23-30. doi: 10.1161/CIRCIMAGING.108.780247.

Reference Type RESULT
PMID: 19808511 (View on PubMed)

Reiter G, Kovacs G, Reiter C, Schmidt A, Fuchsjager M, Olschewski H, Reiter U. Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension. Front Cardiovasc Med. 2022 Aug 3;9:972142. doi: 10.3389/fcvm.2022.972142. eCollection 2022.

Reference Type DERIVED
PMID: 35990987 (View on PubMed)

Reiter U, Kovacs G, Reiter C, Krauter C, Nizhnikava V, Fuchsjager M, Olschewski H, Reiter G. MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension. Eur Radiol. 2021 Apr;31(4):1883-1893. doi: 10.1007/s00330-020-07287-6. Epub 2020 Sep 24.

Reference Type DERIVED
PMID: 32974687 (View on PubMed)

Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsjager M. Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. Radiology. 2015 Apr;275(1):71-9. doi: 10.1148/radiol.14140849. Epub 2014 Nov 5.

Reference Type DERIVED
PMID: 25372980 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PH-06-CMR-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Xenon MRI Pulm Hypertension
NCT04991454 RECRUITING PHASE2
PET/MRI in PAH Patients
NCT03688698 COMPLETED
PET Image in PAH Patients
NCT05452889 RECRUITING EARLY_PHASE1